Phase 1 Trial of MWX401 Injection Now Recruiting

A clinical trial update dated September 4, 2026 reports on a Phase 1 study involving MWX401 Injection, related to angiotensin II. The study is titled "Phase 1 Clinical Study of MWX401 Injection in Chinese Healthy Participants and Participants With Mild Hypertension." According to the listing, the trial is currently in the recruiting status. The study is registered under identifier NCT07803835 and is designated as a Phase 1 trial. The listing indicates the study involves Chinese healthy participants as well as participants with mild hypertension. No outcomes, results, or safety findings have been reported as part of this update. The event data confirms only the trial's registration details, its current recruiting status, and its phase designation. Readers should note that Phase 1 studies are typically early-stage and focus on initial evaluation in human participants. No efficacy or safety conclusions can be drawn from a recruiting status alone. Further updates to this trial's status, including any changes to recruitment or eventual results, would be reported separately as they become available through the official registry. For additional background on angiotensin II, including its approved regulatory status and general context, readers can consult the compound overview.